Seres Therapeutics (MCRB) Rating Lowered to Hold at Zacks Investment Research

Seres Therapeutics (NASDAQ:MCRB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Several other brokerages have also commented on MCRB. CIBC started coverage on shares of Seres Therapeutics in a research note on Friday, October 13th. They issued an “outperform” rating and a $19.00 price target on the stock. Seaport Global Securities restated a “buy” rating and issued a $20.00 price target on shares of Seres Therapeutics in a research note on Friday, October 6th. Oppenheimer started coverage on shares of Seres Therapeutics in a research note on Thursday, October 12th. They issued an “outperform” rating and a $19.00 price target on the stock. Cowen restated a “buy” rating on shares of Seres Therapeutics in a research note on Monday, October 2nd. Finally, Citigroup started coverage on shares of Seres Therapeutics in a research note on Thursday, October 12th. They issued a “positive” rating and a $19.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $18.00.

Shares of Seres Therapeutics (NASDAQ MCRB) traded down $0.19 during trading hours on Wednesday, hitting $10.60. 200,700 shares of the company’s stock traded hands, compared to its average volume of 228,000. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $17.42. The firm has a market capitalization of $433.88 and a price-to-earnings ratio of -5.00. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.11.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The company had revenue of $23.00 million for the quarter, compared to analyst estimates of $17.29 million. During the same quarter last year, the business earned ($0.46) earnings per share. Seres Therapeutics’s revenue was up 76.9% compared to the same quarter last year. sell-side analysts anticipate that Seres Therapeutics will post -2.33 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Seres Therapeutics by 1.2% during the second quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock valued at $17,911,000 after acquiring an additional 19,363 shares during the period. Ark Investment Management LLC increased its stake in shares of Seres Therapeutics by 21.5% during the second quarter. Ark Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock valued at $8,647,000 after acquiring an additional 135,276 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Seres Therapeutics by 39.9% during the third quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock valued at $6,160,000 after acquiring an additional 106,479 shares during the period. State Street Corp increased its stake in shares of Seres Therapeutics by 12.0% during the second quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after acquiring an additional 34,393 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Seres Therapeutics by 16.2% during the second quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after acquiring an additional 32,875 shares during the period. Institutional investors and hedge funds own 75.94% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Seres Therapeutics (MCRB) Rating Lowered to Hold at Zacks Investment Research” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/01/05/seres-therapeutics-mcrb-rating-lowered-to-hold-at-zacks-investment-research.html.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply